EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSUMAG00000017613
Gene Symbol: KCNK2
4 Cross references
280 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSUMAG00000002126
Gene Symbol: KCNK9
2 Cross references
211 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSUMAG00000007733
Gene Symbol: KCNA5
2 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSUMAG00000013918
Gene Symbol: KCND3
4 Cross references
259 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSUMAG00000018080
Gene Symbol: KCNH2
2 Cross references
252 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSUMAG00000022217
Gene Symbol: KCNQ2
3 Cross references
248 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSUMAG00000001380
Gene Symbol: KCNQ3
4 Cross references
191 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSUMAG00000009050
Gene Symbol: PSEN1
4 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSUMAG00000014436
Gene Symbol: PSEN2
4 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSUMAG00000020396
Gene Symbol: PSENEN
4 Cross references
183 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSUMAG00000008495
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSUMAG00000014471
Gene Symbol: PTGER2
4 Cross references
241 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).